Common Contracts
10 similar Underwriting Agreement contracts by Actinium Pharmaceuticals, Inc., Adicet Bio, Inc., Applied Therapeutics Inc., others
3,284,421 SHARES of Common Stock and XCEL BRANDS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 19th, 2024 • XCel Brands, Inc. • Patent owners & lessors • New York
The undersigned, Xcel Brands, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Xcel Brands, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Craig-Hallum Capital Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
27,054,667 Shares And Pre-Funded Warrants to Purchase 8,445,333 Shares Adicet Bio, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 24th, 2024 • Adicet Bio, Inc. • Pharmaceutical preparations • New York
As Representatives of the several Underwriters named in Schedule A attached hereto c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022
UNDERWRITING AGREEMENTUnderwriting Agreement • April 4th, 2023 • SHENGFENG DEVELOPMENT LTD • Trucking & courier services (no air) • New York
The undersigned, Shengfeng Development Limited, a Cayman Islands exempted company (collectively with its subsidiaries, including, without limitation, all entities disclosed or described in the Registration Statement (as defined herein) as being subsidiaries of Shengfeng Development Limited, the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Univest Securities, LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
Applied Therapeutics, Inc. 20,000,000 Shares of Common Stock ($0.0001 par value) and Pre-Funded Warrants to purchase 10,000,000 Shares of Common Stock and Warrants to purchase 30,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 27th, 2022 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
Execution Version Actinium Pharmaceuticals, Inc. Common Stock, par value $0.001 per share, and Warrants to Purchase Common Stock Underwriting Agreement April 18, 2019 William Blair & Company, L.L.C. As representative of the several Underwriters named...Underwriting Agreement • May 5th, 2020 • New York
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”), an aggregate of (i) 42,860,000 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of the Company and (ii) warrants to purchase up to 42,860,000 shares of Common Stock in the form set forth on Exhibit A (the “Warrants” and, together with the Shares, the “Securities”). Each Share is being sold together with a Warrant to purchase one share of Common Stock at an exercise price of $0.50 per whole share of Common Stock. The shares of Common Stock underlying the Warrants are herein called the “Warrant Shares”).
Actinium Pharmaceuticals, Inc. Common Stock, par value $0.001 per share, and Pre-Funded Warrants to Purchase Common Stock Underwriting AgreementUnderwriting Agreement • April 24th, 2020 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom H.C. Wainwright & Co., LLC is acting as representative (the “Representative” or “you”), (A) an aggregate of (i) 100,833,333 shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of the Company and (ii) pre-funded warrants to purchase up to 82,500,001 shares of Common Stock in the form set forth on Exhibit A (the “Warrants” and, together with the Firm Shares, the “Firm Securities”), and (B) subject to the option described in Sections 2 and 4 hereof granted by the Company to the Underwriters, all or any part of 27,500,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Shares” and, together with the Firm Shares, the “Shares”). The shares of Common Stock underlying the Warrants are herein called
DELCATH SYSTEMS, INC. UNDERWRITING AGREEMENT [•] Shares of Common Stock [•] Pre-Funded Warrants to Purchase [•] Shares of Common StockUnderwriting Agreement • February 7th, 2020 • Delcath Systems, Inc. • Surgical & medical instruments & apparatus • New York
Delcath Systems, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Roth Capital Partners, LLC is acting as the representative (the “Representative”), (i) an aggregate of [•] authorized but unissued shares (the “Firm Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”) and (ii) pre-funded warrants (the “Firm Pre-Funded Warrants”) to purchase up to an aggregate of [•] shares of Common Stock at an exercise price of $0.01 per share (the “Firm Pre-Funded Warrant Shares”). The Firm Shares, the Firm Pre-Funded Warrants, and the Firm Pre-Funded Warrant Shares are collectively referred to as the “Firm Securities.” The Company also proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters, (i) an aggregate of [•] authorized but unissued shares
Actinium Pharmaceuticals, Inc. Common Stock, par value $0.001 per share, and Warrants to Purchase Common Stock Underwriting AgreementUnderwriting Agreement • April 18th, 2019 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”), an aggregate of (i) 42,860,000 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of the Company and (ii) warrants to purchase up to 42,860,000 shares of Common Stock in the form set forth on Exhibit A (the “Warrants” and, together with the Shares, the “Securities”). Each Share is being sold together with a Warrant to purchase one share of Common Stock at an exercise price of $0.50 per whole share of Common Stock. The shares of Common Stock underlying the Warrants are herein called the “Warrant Shares”).
SYROS PHARMACEUTICALS, INC. 8,667,333 shares of common stock, par value $0.001 per share (the “Common Stock”) and Class A Warrants to Purchase up to 1,951,844 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • April 8th, 2019 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), (i) an aggregate of 8,667,333 shares of Common Stock of the Company (the “Shares”) and (ii) Class A Warrants, substantially in the form of Exhibit A hereto, to purchase an aggregate of 1,951,844 shares of Common Stock (the “Warrants,” such Shares and Warrants to be issued and sold by the Company being hereinafter collectively called the “Securities”). Each share was offered by the Company together with a Warrant to purchase one-quarter of one share of Common Stock at an exercise price of $8.625 per whole share; provided, that 859,957 of the Shares to be sold hereunder are being sold without such Warrants. As used herein, “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrants. The shares of Common Stock of the Compa
Class B Warrants to Purchase One Share of Common StockUnderwriting Agreement • May 12th, 2015 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named on Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Maxim Group LLC and Roth Capital Partners, LLC are acting as joint bookrunning managers (in such capacity, together the “Joint Bookrunners” and each, a “Joint Bookrunner”) and National Securities Corporation is acting as co-manager an aggregate of [____] shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company and [___] class A warrants (the “Class A Warrants”) and [____] class B warrants (the “Class B Warrant” and collectively, with the Class A Warrants, the “Firm Warrants”), each Class A Warrant entitles the holder to purchase one share of Common Stock at an exercise price of $[____] per share at any time prior to the expiration thereof on [____] and each Class B Warrant entitle
